(NP (NP (JJ Transient) (NN pseudohypoaldosteronism)) (PP (IN in) (NP (JJ obstructive) (JJ renal) (NN disease))) (PP (IN with) (NP (NP (JJ transient) (NN reduction)) (PP (IN of) (NP (JJ lymphocytic) (NN aldosterone) (NNS receptors))))) (. .))
(NP (NP (NNS Results)) (PP (IN in) (NP (CD two) (JJ affected) (NNS infants))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP report) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (NP (JJ transient) (NN pseudohypoaldosteronism)) (PP (JJ due) (TO to) (NP (JJ obstructive) (JJ renal) (NN disease))))))) (. .))
(S (NP-SBJ (DT Both) (NNS patients)) (VP (VBD presented) (PP (IN with) (NP (DT a) (JJ salt-losing) (NN episode) (VBG simulating) (JJ adrenal) (NN insufficiency)))) (. .))
(S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP-SBJ-90 (NP (JJ transient) (NN reduction)) (PP (IN of) (NP (NN aldosterone) (NNS receptors)))) (VP (MD could) (VP (VB be) (VP (VBN documented) (NP (-NONE- *-90)) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (DT the) (JJ second) (NN patient))) (NP-SBJ (DT the) (ADJP-COOD (ADJP (JJ clinical)) (CC and) (ADJP (JJ biochemical))) (NNS parameters)) (VP (VBD were) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (JJ transient) (NN pseudohypoaldosteronism)))))))))) (. .))
(S (NP-SBJ-91 (NN Aldosterone) (NNS receptors)) (VP (VBD were) (ADJP-PRD (JJ normal)) (PP (IN in) (NP (DT both) (NNS patients))) (SBAR-TMP (WHADVP-92 (IN when)) (S (NP-SBJ-93 (-NONE- *-91)) (VP (VBN studied) (NP (-NONE- *-93)) (PP-TMP (IN after) (NP (NP (DT the) (JJ surgical) (NN correction)) (PP (IN of) (NP (DT the) (NN obstruction))))) (ADVP (-NONE- *T*-92)))))) (. .))
